**Appropriate Use Criteria for Coronary Revascularization in Patients with Acute Coronary Syndromes: Members of the Writing Group, Rating Panel, Indication Reviewers, and AUC Task Force—Relationships with Industry and Other Entities (Comprehensive)**

Note: A standard exemption to the ACC RWI policy is extended to Appropriate Use Criteria writing groups, since they do not make recommendations but rather prepare background materials and typical clinical scenarios/indications that are rated independently by a separate panel of experts.

| **Participant** | **Employment** | | **Consultant** | | | **Speaker’s Bureau** | | **Ownership/ Partnership/ Principal** | | **Personal Research** | **Institutional, Organization-al, or Other Financial Benefit** | | **Expert Witness** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Writing Group** | | | | | | | | | | | | | |
| Manesh R. Patel (Chair) | Duke University Health System, Duke Clinical Research Institute —Associate Professor of Medicine, Director Interventional Cardiology and Catheterization Labs | | | Bayer Healthcare†  • Genzyme  • Medscape - theheart.org  • Merck  • Duke CME | | None | | None | | • AHQR (Co-PI)  • Astra Zeneca – General Cardiology (Co-PI)†  • Jansen (Co-PI)  • Johnson & Johnson – Arrhythmias & Clinical EP (Co-PI)†  • Maquet (Co-PI)  • Nat’l Heart Lung & Blood Inst - Noninvasive Imaging (Co-PI)†  • PCORI (Co-PI)  Nat’l Heart Lung & Blood Inst - Noninvasive Imaging (PI) \* | None | | None | |
| John H. Calhoon | University of Texas Health Science Center at San Antonio Department of Cardiothoracic Surgery, Heart and Vascular Institute Director —Professor and Chair, Presidents Council Chair for Excellence in Surgery | | | None | | None | | None | | None | None | | None | |
| Gregory J. Dehmer | Baylor Scott & White - Temple Memorial,Texas A&M Health Science Center College of Medicine, Central Texas Division —Clinical Professor of Medicine, Medical Director, Cardiovascular Services, Director, Cardiology Division | | | • Member - FDA Circulatory System Devices Panel of the Medical Devices Advisory  • Past President - Society for Cardiovascular Angiography & Interventions\* | | None | | None | | None | • Baylor Scott & White Health† | | None | |
| James Aaron Grantham | Saint Luke's Hospital — Associate Clinical Professor, University of Missouri–Kansas City School of Medicine — Director, Cardiovascular Disease Fellowship Program, Director, Cardiovascular Medical Education | | | • Abbott  Vascular, Inc†  • Asahi-Intecc†  • Boston  Scientific†  • Bridgepoint Medical Systems†  • Medtronic† | | None | | None | | • Abbott Vascular, Inc - Invasive CV Angio & Interventions(Co-PI) †  • Asahi-Intecc - Invasive CV Angio & Interventions(Co-PI) †  • Boston  Scientific - Invasive CV Angio & Interventions(Co-PI) †  • Bridgepoint Medical Systems - Invasive CV Angio & Interventions(Co-PI) †  •Medtronic - Invasive CV Angio & Interventions(Co-PI) † | None | | None | |
| Thomas M. Maddox | VA Eastern Colorado Health Care System — National Director, Associate Professor, Department of Medicine, Cardiology, University of Colorado, Colorado Cardiovascular Outcomes Research Consortium | | | None | | •Creative Educational Concepts CME† | | None | | None | None | | None | |
| David J. Maron | Stanford University School of Medicine — Clinical Professor of Medicine, Cardiovascular, Director, Preventive Cardiology | | | None | | None | | None | | •NIH-NHLBI ISCHEMIA Trial Grant 1Uo1HL105907 – Noninvasive Imaging Prevention Invasive CV Angio & Interventions Cardiothoracic Surgery General Cardiology (PI)† | None | | None | |
| Peter K. Smith | Cardiovascular and  Thoracic Surgery, Duke University — Professor of Surgery, Division Chief | | | None | | None | | None | | None | None | | None | |
| **Rating Panel** | | | | | | | | | | | | | |
| James C. Blankenship | Geisinger Medical Center, Division of Cardiology — Staff Physician, Director, Cardiac Catheterization Laboratory | | •US Dept Health & Human Services | | | None | | None | | • Abbott  Vascular, Inc - Invasive CV Angio & Interventions (Co-PI)\*  • American Board of Internal Medicine - Invasive CV Angio & Interventions (PI)\*  • Am College Cardiology to AMA Relative Value Update Committee (PI)\*  • AstraZeneca - Invasive CV Angio & Interventions (Co-PI)\*  • Boston  Scientific - Invasive CV Angio & Interventions (Co-PI)\*• GlaxoSmith-Kline – Acute Coronary Syndromes\*  • Hamilton  Health  Sciences – Acute Coronary Syndromes (Co-PI)\*  • Medinal LTD - Acute Coronary Syndromes (Co-PI)\*\*  • Orexigen Therapeutics/Takeda - Acute Coronary Syndromes (Co-PI)\*\*  • Society of Angiography & Interventions -Invasive CV Angio & Interventions (PI)\*  • Stentys,Inc - Acute Coronary Syndromes (Co-PI)\*  • St. Jude Medical – Congenital Heart Disease & Pediatric Cardiology (Co-PI)\*  • Takeda Pharmaceutic-als – Acute Coronary Syndromes (Co-PI)\* | •Geisinger Medical Center† | | None | |
| Alfred A. Bove | Temple University, Lewis Katz School of Medicine, Heart and Vascular —Professor Emeritus | | • Elsevier Publishing Co  •Insight Telehealth Inc\*  • Merck Manual  •Underwater Medicine Associates | | | None | | •Insight Telehealth,Inc\* | | •Merck Schering Plough – Prevention (Co-PI) † | None | | None | |
| Steven M. Bradley | VA Eastern Colorado Health Care System, Division of Cardiology at the University of Colorado — Staff Cardiologist, Assistant Professor of Medicine | | • Heart Journal†  •Workgroup for the development, reevaluation & Implementation of Hospital Outcome/ EfficiencyMeasures, Centers for Medicare & Medicaid Services | | | None | | None | | • Collaborative Care to Alleviate Symptoms & Adjust to Illness Study (DSMB)\*  • Univ of Colorado Dept of Medicine Early Career Scholars Program – Stable Ischemic Heart Disease (PI)\*  •VA HSR&D Career Development Award (HSR&D-CDA2 10-199) – Other Invasive CV Angio & Interventions (PI) †  • VA HSR&D Investigator Initiated Project (HSR&D IIR 13-079-2; 1 I01 HX001276-01)  •VA HSR&D Investigator Initiated Project (HSR&D IIR 14-338-3; 1 I01 HX001778- 01A2) - Invasive CV Angio & Interventions (PI)\*  • VA HSR&D Investigator Initiated Project (HSR&D IIR 15-139) – Arrhythmias & Clinical EP (PI)\*  •VA QuERI Program Project (HX 15-019) – Stable Ischemic Heart Disease (PI)\* |  | | None | |
| Larry S. Dean | Medicine Regional Heart Center University of Washington School of Medicine, Professor of Medicine and Surgery, Director | | •Philips Medical | | | None | | None | | •Edwards Life Sciences – Invasive CV Angio & Interventions (Co-PI)† | •Emageon | | None | |
| Peter L. Duffy | First Health of the Carolinas, Reid Heart Institute/Moore Regional Hospital — Director of Quality for the Cardiovascular Service Line | | None | | | •Volcano Corp† | | None | | None | •Janssen Research & Development ‡  • Medinol LTD ‡  • Thrombosis Research Institute ‡ | | None | |
| T. Bruce Ferguson, Jr., | East Carolina Heart Institute, East Carolina University, Department of Cardiovascular Sciences, Cardiothoracic Surgery — Professor of Thoracic Surgery | | None | | | None | | •RFPi, LLC \* | | •Novadaq Technologies -Cardiothoracic Surgery (Co-PI)† | •NIH | | None | |
| Frederick L. Grover | University of Colorado, Department of Cardiothoracic Surgery — Professor of Cardiothoracic Surgery | | • American College of Cardiology Program Committee\*  •National Quality Forum Surgery Standing Committee\*  •Stanford Clinical Excellence Research Center, America’s Most Valuable Care Project – Cardiothoracic Surgery (Co-PI)†  • Somalution (Co-PI) | | | None | | None | | • ACC – Stable Ischemic Heart Disease (PI) \*  • ACC – Acute Coronary Syndromes (PI)\*  • Acert Steering Committee – Cardiothoracic Surgery (PI) \*  • Society of Thoracic Surgeons – Cardiothoracic Surgery (PI)\*  •STS/ACCF TVT Steering Committee – Cardiothoracic Surgery Invasive CV Angio & Interventions (PI)\* | None | | None | |
| Robert A. Guyton | Emory University School of Medicine, Division of Cardiothoracic Surgery, Department of Surgery, Thoracic Surgery Residency Program — Chief of Cardiothoracic Surgery, Professor of Surgery Director | | •Medtronic† | | | None | | None | | •NIH – Cardiothoracic Surgery (PI)\* | None | | None | |
| Mark A. Hlatky | Stanford University School of Medicine, Cardiovascular Medicine, Health Services Research — Professor of Heath Research and Policy, Professor of Medicine | | •Acumen†  •Genentech, Inc  •American College of Cardiology†  •Blue Cross Blue Shield Center for Effectiveness Evaluation† | | | None | | None | | •George Institute – General Cardiology (PI)  •Heartflow – Noninvasive Imaging  (Co-PI)†  •National Heart Lung & Blood Institute  (DSMB)  •Sanofi- Aventis – General Cardiology (Co-PI) | None | | None | |
| Harold L. Lazar | Boston University School of Medicine, Cardiothoracic Research Program — Director Professor of Cardiothoracic Surgery | | None | | | None | | None | | •Eli Lilly – Cardiothoracic Surgery (PI)  •Paraxel International†  (DSMB) | •Journal of Cardiac Surgery Wiley - Blackwell† | | None | |
| Vera H. Rigolin | Northwestern University Feinberg School of Medicine, Cardiology — Professor | | None | | | None | | None | | None | • Pfizer† | | None | |
| Geoffrey A. Rose | Division of Cardiology, Sanger Heart and Vascular Institute —Chief | | None | | | None | | None | | None | • Abbott Laboratories‡  • Intersocietal Accreditation Commission (Officer)\*  • Medtronic | | None | |
| Richard J. Shemin | Ronald Reagan UCLA Medical Center, Cardiovascular Center — Director of Cardiac Quality,  Robert and Kelly Day Professor, Chief of Cardiothoracic Surgery, Executive Vice Chair of Surgery | | • Atricure  • Edwards Lifesciences  • Sorin Group | | | None | | None | | None | None | | • Defendant, Mitral Valve Malpractice, 2016 | |
| Jacqueline E. Tamis-Holland | Saint Luke's Hospital, Icahn School of Medicine at Mount Sinai Hospital Mount Sinai — Director, Women's Heart NY, Assistant Professor of Medicine, Director, Interventional Cardiology Fellowship | | None | | | None | | None | | • The NGS-PREDICT Study- Stable Ischemic Heart Disease (PI) \*  • ISCHEMIA Trial- General Cardiology Cardiothoracic Surgery Invasive CV Angio & Interventions (PI)†  • NIH‡ | •Interventional Cardiology Fellowship, Program Director\*  • Women' Heart NY† | | None | |
| Carl L. Tommaso | Rush Medical College in Chicago, Skokie Illinois Hospital, part of the Northshore University Health System — Director of the Cardiac Catheterization Laboratory, Associate Professor of Medicine | | • SCAI\* | | | None | | None | | None | None | |  | |
| L. Samuel Wann | Columbia St. Mary’s Healthcare — Clinical Cardiologist, Medical Director, Heart Failure Program | | • United Healthcare | | | None | | None | | None | None | | None | |
| John B. Wong | Tufts University School of Medicine — Chief, Division of Clinical Decision Making, Primary Care Physician, Principal Investigator, Institute for Clinical Research and Health Policy Studies, Professor | | • American College of Physicians  • Informed Medical Decisions Foundation | | | None | | None | | • Patient-Centered Outcome Research Institute – Cardiothoracic Surgery Congenital Heart Disease & Pediatric Cardiology Invasive CV Angio & Interventions Prevention Stable Ischemic Heart Disease(PI)† | • AMA Physician Consortium for Performance Improvement\* | | None | |
| **Reviewers** | | | | | | | | | | | | | |
| Jeffrey L. Anderson | Intermountain Medical Center — Associate Chief of Cardiology | • Medicines Company  • Sanofi-Aventis | | | None | | None | | • Academic Research Group (DSMB)  • Harvard – TIMI -48,51,52, 60 Studies (DSMB)  • ICON Clinical Research  • NIH - COAG Study (PI)\*  • NIH - GIFT Study (PI)\*  • NIH - ISCHEMIA Study (DSMB) \* | |  | | None |
| Jeffrey A. Brinker | Johns Hopkins Hospital—Professor of Medicine | None | | | None | | None | | None | | None | | None |
| Alexandru I. Costea | University of  Cincinnati  Medical  Center—Associate Professor | None | | | • Biotronik | | None | | None | | • Boston Scientific \*  • Multicenter Trial industry sponsored \*  • NIH ‡ | | None |
| Ali E. Denktas | Baylor College of Medicine—Assistant Professor | None | | | None | | None | | • Astra Zeneca – General Cardiology (PI)  • Edwards – Invasive CV Angio & Interventions (PI)\* | | • Astra Zeneca ‡ | | None |
| Lloyd W. Klein | Melrose Park—Professor of Medicine | None | | | None | | None | | None | | None | | None |
| Frederick G. Kushner | Tulane University Medical Center, Heart Clinic of Louisiana—Clinical Professor, Medical Director | None | | | None | | None | | None | | None | | None |
| Glenn N. Levine | Baylor College of Medicine, Cardiology—Professor | None | | | None | | None | | None | | None | | • Defendant, Hospital Death, 2016  • Defendant, Catheterization Laboratory Procedure, 2016 |
| David J. Maron | Stanford University School of Medicine—Professor of Medicine and Emergency Medicine | None | | | None | | None | | •NIH-NHLBI ISCHEMIA Trial Grant 1Uo1HL105907 – Noninvasive Imaging Prevention Invasive CV Angio & Interventions Cardiothoracic Surgery General Cardiology (PI)† | | None | | None |
| James B. McClurken | Temple University, School of Medicine, Richard A Reif Heart Institute, Doylestown Hospital—Director of Thoracic Surgery,  Professor of Surgery Emeritus | None | | | None | | None | | • Society of Thoracic Surgeons National Database Committee (PI) \* | | • Sub-Investigator – Silver AMI Study\* | | None |
| Robert N. Piana | Vanderbilt University Medical Center—Professor of Medicine, Cardiology | • Axio Research  • HCRI  • W.L. Gore & Associates, Inc. | | | None | | None | | • Terumo (DSMB) | | •Cardiovascular Peer Review †  • Doris Duke Charitable Foundation ‡  • Duke Clinical Research Institute/OrbusNEich ‡  • St. Jude Medical ‡ | | None |
| John A. Spertus | Washington University School of Medicine—Adjunct Professor of Medicine | • Amgen  • Bayer Healthcare Pharmaceuticals  • Copyright for SAQ, KCCQ, PAQ †  • Janssen  • Novartis †  • United Healthcare Scientific Advisory Board | | | None | | • Health Outcomes Sciences † | | • American College of Cardiology –Invasive CV Angio & Interventions (Co-PI) †  • American Heart Association – General Cardiology (PI)\*  • CV Outcomes –General Cardiology (PI)\*  • Lilly –General Cardiology (Co-PI) † | | None | | None |
| Raymond F. Stainback | Texas Heart Institute at Baylor St. Luke's Medical Center, Non-Invasive Cardiology— Medical Director | None | | | None | | None | | None | | None | | None |
| Robert C. Stoler | Cardiology Consultants of Texas—Director of Cardiac Catheterization Laboratory | • Arrow  • Boston Scientific  • Medtronic † | | | None | | None | | None | | • Baylor Heart & Vascular Hospital†  • Abbott Laboratories‡  • Boston Scientific‡  •Medtronic‡  • Tendyne‡ | | None |
| Todd C. Villines | Cardiology Service at Walter Reed Army Medical Center— Co-Director of Cardiovascular Computed Tomography and Assistant Chief | • Boehringer Ingelheim Pharmaceutical† | | | None | | None | | None | | None | | None |
| David H. Wiener | Jefferson Medical College, Jefferson Heart Institute—Professor of Medicine | None | | | None | | None | | None | | None | | None |
| **Appropriate Use Criteria Task Force** | | | | | | | | | | | | | |
| Steven R. Bailey | University of Texas Health Sciences Center —Chair, Division of Cardiology, Professor of Medicine and Radiology, Janey Briscoe Distinguished Chair | | None | | | None | | None | | None | | • Edwards‡ | None | |
| Nicole Bhave | University of Michigan Cardiovascular Center, Department of Internal Medicine, Division of Cardiovascular Medicine—Clinical Assistant Professor | | None | | | None | | None | | None | | None | None | |
| Alan S. Brown | Midwest Heart Disease Prevention Center, Advocate Lutheran General Hospital—Director, Division of Cardiology— Medical Director | | • Aksea  • Amgen, Inc†  • Astra Zeneca  • Kastle  • Regeneron† | | | None | | None | | None | | • American Society for Preventative Cardiology\*  • Astra Zeneca/Cleveland Clinic‡  • National Lipid Association, Officer\* | None | |
| Stacie L. Daugherty | University of Colorado School of Medicine, Division of Cardiology, Department of Medicine — Associate Professor | | None | | | None | | None | | • American Heart Association - General Cardiology (PI)†  • NHLBI Blair RO1 – General Cardiology (PI)  • NHLBI Award (PI)† | | None | None | |
| Gregory J. Dehmer | Baylor Scott & White, Central Texas Division, Cardiovascular Services Health — Medical Director | | • Member - FDA Circulatory System Devices Panel of the Medical Devices Advisory  • Past President - Society for Cardiovascular Angiography & Interventions\* | | | None | | None | | None | | • Baylor Scott & White Health† | None | |
| Milind Y. Desai | Cleveland Clinic, Clinical Investigations, Heart and Vascular Institute — Associate Director | | None | | | None | | None | | None | | None | None | |
| John U. Doherty | Thomas Jefferson University, Jefferson Medical College — Professor of Medicine | | None | | | None | | None | | None | | None | None | |
| Claire Duvernoy | University of Michigan Health System, Division of Cardiology — Cardiology Section Chief | | None | | | None | | None | | None | | • VA Cooperative Studies Program\* | None | |
| Linda D. Gillam | Morristown Medical Center, Department of Cardiovascular Medicine – Chair | |  | | | None | | None | | •Bracco – Noninvasive Imaging  (Co-PI)\*  •Edwards Lifesciences – Cardiothoracic Surgery (Co-PI)\*  •Medtronic - Valvular Heart Disease(Co-PI)\* | | • Abbott Vascular‡  • Bracco ‡  • Circulation Imaging, Officer  • National Board of Echocardiography, Officer\* | None | |
| Robert C. Hendel | Miami University School of Medicine, Division of Cardiology — Director of Cardiac Imaging and Outpatient Services | | • Astellias Pharma† | | | None | | None | | None | | None | None | |
| Christopher M. Kramer | University of Virginia Health System — Ruth C. Heede Professor of Cardiology & Radiology, Director, Cardiovascular Imaging Center | | • Gilead  • MyoKardia  • St. Jude’s Medical | | | None | | None | | • Novartis –Noninvasive Imaging (Co-PI)†  • NHLBI –R01 Grant /Noninvasive Imaging (PI)† | | • Bayer Healthcare Pharmaceuticals ‡ | None | |
| Bruce D. Lindsay | Cleveland Clinic Foundation of Cardiovascular Medicine — Professor of Cardiology | | • Abbott  • Bioscience Webster  • Boston Scientific†  • CardioInsight†  • Medtronic†  • St. Jude † | | | None | | None | | None | | • Medtronic † | None | |
| Warren J. Manning | Beth Israel Deaconess Medical Center, Division of Cardiology — Professor of Medicine and Radiology | | •Merck & Co | | | None | | • General Electric† | | •Philips Medical Systems – Noninvasive Imaging (PI)† | | • Samsung Electronics† | • Plaintiff, Endocarditis† | |
| Manesh R. Patel | Duke University Medical Center, Division of Cardiology — Assistant Professor of Medicine | | • Bayer Healthcare†  • Duke CME  • Genzyme  • Medscape – The Heart.org  • Merck | | | None | | None | | • AHQR (Co-PI)  • Astra Zeneca – General Cardiology (Co-PI)†  • Jansen (Co-PI)  • Johnson & Johnson – Arrhythmias & Clinical EP (Co-PI)†  • Maquet (Co-PI)  • Nat’l Heart Lung & Blood Inst - Noninvasive Imaging (Co-PI)†  • PCORI (Co-PI)  Nat’l Heart Lung & Blood Inst - Noninvasive Imaging (PI ) | | None | None | |
| Ritu Sachdeva | Emory University School of Medicine, Children’s Health Care of Atlanta, Sibley Heart Center Cardiology, Division of Pediatric Cardiology, Department of Pediatrics — Associate Professor | | None | | | None | | None | | None | | None | None | |
| L. Samuel Wann | Columbia St. Mary's Healthcare — Staff Cardiologist | | • United Healthcare | | | None | | None | | None | | None | None | |
| David Winchester | University of Florida, Division of Cardiology — Assistant Professor of Medicine | | None | | | None | | None | | • NHLBI ISCHEMIA Trial – General Cardiology (PI)\* | | • Alachua County Medical Society – Board of Directors\*  • Florida Chapter of ACC – Board of Directors\*  • Roche  • Society of Cardiovascular Patient Care – Officer\* | None | |
| Joseph M. Allen | American College of Cardiology – Team Leader, Clinical Policy and Pathways | | None | | | None | | None | | None | | None | None | |

This table represents relevant relationships of participants with industry and other entities that were reported by reviewers at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

\* No financial benefit

† Significant relationship